Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
Cinclus Pharma is proud to be the Gold Sponsor of the OESO-SEMPIRE World Conference in Esophagology
This international congress brings together leading experts, researchers and healthcare professionals from around the world to share knowledge, discuss the latest advances in esophagology, and shape the future of esophageal care and treatment.
Cinclus Pharma participates in Digestive Disease Week (DDW) in Chicago May 2-5 2026
DDW brings together experts from across the globe for a comprehensive program of scientific sessions and networking opportunities.
CEO Christer Alhberg presents at Redeye Healthcare Day 2026
Watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at Redeye Healthcare Day 2026.
From summer job to groundbreaking research
Interview with Kjell Andersson – co-founder, Chief Scientific Officer, and since January 2026, board member of Cinclus Pharma
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
